Atrion (ATRI) Raised to “Sell” at BidaskClub

Atrion (NASDAQ:ATRI) was upgraded by equities researchers at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued on Thursday.

Shares of Atrion stock opened at $604.70 on Thursday. Atrion has a twelve month low of $516.85 and a twelve month high of $694.00. The firm has a market capitalization of $1.09 billion, a P/E ratio of 31.00 and a beta of 0.63.

Atrion (NASDAQ:ATRI) last issued its quarterly earnings data on Wednesday, May 9th. The medical instruments supplier reported $4.56 EPS for the quarter. The company had revenue of $39.40 million for the quarter. Atrion had a return on equity of 19.34% and a net margin of 23.82%.

Several institutional investors and hedge funds have recently modified their holdings of ATRI. Bank of Montreal Can lifted its stake in shares of Atrion by 25.7% during the fourth quarter. Bank of Montreal Can now owns 597 shares of the medical instruments supplier’s stock worth $376,000 after purchasing an additional 122 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its stake in shares of Atrion by 1.7% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 6,972 shares of the medical instruments supplier’s stock worth $4,397,000 after purchasing an additional 115 shares in the last quarter. American Century Companies Inc. lifted its stake in shares of Atrion by 34.3% during the fourth quarter. American Century Companies Inc. now owns 2,186 shares of the medical instruments supplier’s stock worth $1,378,000 after purchasing an additional 558 shares in the last quarter. Teacher Retirement System of Texas acquired a new position in shares of Atrion during the fourth quarter worth about $323,000. Finally, California Public Employees Retirement System lifted its stake in shares of Atrion by 3.2% during the fourth quarter. California Public Employees Retirement System now owns 4,320 shares of the medical instruments supplier’s stock worth $2,724,000 after purchasing an additional 132 shares in the last quarter. Institutional investors own 58.74% of the company’s stock.

Atrion Company Profile

Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply